Valiant LaboratoriesNSE:VALIANTLAB -0.06%51 PB Ratio is 1.19 as of Jun. 26, 2026, which is 43% below its 10-year median of 2.08. GuruFocus rates NSE:VALIANTLAB with a GF Score™ of 51/100 and a GF Value™ of ₹103.25 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 922 Drug Manufacturers companies, Valiant Laboratories ranks better than 69.52% on this metric.
The historical rank and industry rank for Valiant Laboratories's PB Ratio or its related term are showing as below:
NSE:VALIANTLAB'
s PB Ratio Range Over the Past 10 Years
Min: 0.98 Med: 2.08 Max: 7.93
Current: 1.19
During the past 6 years, Valiant Laboratories's highest PB Ratio was 7.93. The lowest was 0.98. And the median was 2.08.
NSE:VALIANTLAB's PB Ratio is ranked better than 69.52% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.825
vs NSE:VALIANTLAB: 1.19
During the past 12 months, Valiant Laboratories's average Book Value Per Share Growth Rate was 14.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 38.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 32.90% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Valiant Laboratories was 48.60% per year. The lowest was 38.70% per year. And the median was 38.80% per year.
Back to Basics: PB Ratio
Valiant Laboratories (NSE:VALIANTLAB) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Valiant Laboratories PB Ratio Related Terms
Valiant Laboratories PB Ratio Historical Data
* Premium members only.
The historical data trend for Valiant Laboratories's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Valiant Laboratories's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valiant Laboratories PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Valiant Laboratories's PB Ratio distribution charts can be found below:
* The bar in red indicates where Valiant Laboratories's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Valiant Laboratories (NSE:VALIANTLAB) has a PB Ratio of 1.19 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Valiant Laboratories and its competitors. This is 43% below median its historical median of 2.08. Over the past decade, Valiant Laboratories' PB Ratio has ranged from 0.98 to 7.93. According to the industry distribution chart, Valiant Laboratories ranks #281 out of 922 companies in the Drug Manufacturers industry, placing it in the top 30.5%.
Is Valiant Laboratories' PB Ratio too high?
Valiant Laboratories' current PB Ratio of 1.19 is 43% below median its 10-year median of 2.08. Over the past 10 years, this metric has ranged from a low of 0.98 to a high of 7.93. The Drug Manufacturers industry median PB Ratio is 1.83. Valiant Laboratories' value of 1.19 is 34.8% below this industry median. Based on the distribution chart, Valiant Laboratories ranks #281 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Valiant Laboratories has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valiant Laboratories' PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Valiant Laboratories ranks #281 out of 922 companies for PB Ratio. This puts Valiant Laboratories in the upper half of its industry. The industry median PB Ratio is 1.83. Valiant Laboratories' value of 1.19 is 34.8% below this benchmark. Historically, Valiant Laboratories' own PB Ratio has ranged from 0.98 to 7.93 over the past decade. While the company's 10-year median is 2.08 vs. the industry median of 1.83, Valiant Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.83, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valiant Laboratories's current PB Ratio of 1.19 is 34.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Valiant Laboratories and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valiant Laboratories's current PB Ratio is 1.19, which is 43% below median its own 10-year median of 2.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valiant Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Valiant Laboratories (NSE:VALIANTLAB) is currently considered Possible Value Trap. The stock's GF Value™ is ₹103.25, compared to a current price of ₹68.00 — trading 34.1% below its estimated fair value. The current PB Ratio is 1.19, which is 43% below median its 10-year median of 2.08 and 34.8% below the Drug Manufacturers industry median of 1.83. Valiant Laboratories' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Valiant Laboratories (NSE:VALIANTLAB), the current PB Ratio is 1.19 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valiant Laboratories (NSE:VALIANTLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Valiant Laboratories stock appears to be undervalued.
The current stock price of ₹68.00 is trading 34.1% below its estimated GF Value™ of ₹103.25.
GuruFocus considers Valiant Laboratories to be Possible Value Trap.
Key valuation signals for NSE:VALIANTLAB:
PB Ratio: 1.19 (43% below median its 10-year median of 2.08)
GF Value™: ₹103.25 vs. price of ₹68.00 (34.1% below fair value)
Industry Position: 34.8% below the Drug Manufacturers median (#281 of 922)
No single metric tells the full story. See the NSE:VALIANTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valiant Laboratories Ltd is an Active Pharmaceutical Ingredient (API)/Bulk Drug manufacturing company with having focus on manufacturing Paracetamol. Paracetamol is one of the widely used analgesics globally and is recommended as the first-line therapy in pain conditions by the World Health Organization. Paracetamol has several applications such as usage in the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. It manufactures Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers.
51GF Score
Get the complete analysis for NSE:VALIANTLAB
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VALIANTLAB has been successfully added to your 
